CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: PLEKHG2 (ImmuneEditome ID:64857)

1. Gene summary of enriched editing regions for PLEKHG2

check button Gene summary
Gene informationGene symbol

PLEKHG2

Gene ID

64857

GeneSynonymsARHGEF42|CLG|CTB-60E11.4|LDAMD
GeneCytomap

19q13.2

GeneTypeprotein-coding
GeneDescriptionpleckstrin homology domain-containing family G member 2|PH domain-containing family G member 2|common-site lymphoma/leukemia guanine nucleotide exchange factor|pleckstrin homology domain containing, family G (with RhoGef domain) member 2
GeneModificationdate20230329
UniprotIDQ9H7P9;E7ESZ3;C9J7S4;M0R3J0;C9JVL3;M0QX05;M0QZT7;M0R391
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr19:39426895-39428210:+ENST00000425673.4ENSG00000090924.13PLEKHG2UTR3MIR,AluSx1,AluY,AluSq2,AluSz6chr19:39426895-39428210:+.alignment


Top

2. Tumor-specific enriched editing regions for PLEKHG2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr19:39426895-39428210:+LUADEER2.9934e-02image
ENSG00000090924.13,PLEKHG2LUADEAG3.0188e-02image
chr19:39426895-39428210:+LUSCEER2.8837e-03image
ENSG00000090924.13,PLEKHG2LUSCEAG2.8837e-03image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr19:39426895-39428210:+READPathEER7.2972e-031.1145e-02-0.4988image
ENSG00000090924.13,PLEKHG2READPathEAG7.2972e-031.1145e-02-0.4988image
ENSG00000090924.13,PLEKHG2TGCTPathEAG3.8450e-021.1905e-02-0.3282image
chr19:39426895-39428210:+TGCTPathEER3.8450e-021.1905e-02-0.3282image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for PLEKHG2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr19:39426895-39428210:+UCECEERENSG00000168827,GFM10.42971.0871e-041.8355e-080.4292imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:39426895-39428210:+UCECEERENSG00000137055,PLAA0.42451.7718e-041.2855e-080.4334imageNELAVL1;FBL;FMR1;NOP56;U2AF2PLAAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:39426895-39428210:+UCECEERENSG00000184575,XPOT0.42131.9255e-045.2663e-080.4164imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chr19:39426895-39428210:+UCECEERENSG00000136628,EPRS0.40174.7982e-041.0289e-070.4080imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr19:39426895-39428210:+UCECEERENSG00000163754,GYG10.39476.7645e-042.6473e-080.4248imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAGSVA_HALLMARK_MYC_TARGETS_V1
chr19:39426895-39428210:+UCECEERENSG00000071794,HLTF0.37391.3651e-036.9812e-080.4129imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAEosinophilsGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:39426895-39428210:+UCECEERENSG00000169598,DFFB0.34882.8937e-036.9037e-080.4131imageNELAVL1;FBL;FMR1;NOP56;U2AF2DFFBPlasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
chr19:39426895-39428210:+UCECEERENSG00000077713,SLC25A430.34943.5959e-037.6305e-080.4118imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAEosinophilsGSVA_HALLMARK_PROTEIN_SECRETION
chr19:39426895-39428210:+DLBCEERENSG00000268205,CTC-444N24.11-0.58921.6320e-028.8132e-04-0.4645imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAB_cells_memoryGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr19:39426895-39428210:+DLBCEERENSG00000164494,PDSS20.54183.0709e-023.4798e-040.4950imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for PLEKHG2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000099840.9chr192097928:2098127:2098286:2098334-0.41061.7142e-044.2470e-08-0.4401imageNBCCIP;BUD13;CSTF2T;DDX42;EIF4A3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;HNRNPM;HNRNPU;KHSRP;LIN28;LIN28A;LSM11;NONO;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000129968.11chr191877507:1877647:1879920:1880017-0.38041.4629e-032.6826e-08-0.4259imageNADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMacrophages_M0GSVA_HALLMARK_FATTY_ACID_METABOLISM
chr19:39426895-39428210:+
GBMEERIRENSG00000099840.9chr192098435:2098450:2098786:2098804-0.33141.3988e-034.6962e-07-0.4459imageNFBL;FMR1;U2AF2NAMonocytesGSVA_HALLMARK_PEROXISOME
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000125458.2chr1775130224:75130867:75131044:75131105-0.41644.6674e-041.7795e-07-0.4010imageNAIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000169733.7chr1782049676:82050555:82050661:82050759-0.42152.9540e-046.6382e-08-0.4124imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MOV10;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000106077.14chr773736093:73736691:73736928:73736990-0.39897.1535e-041.6298e-07-0.4021imageNADAR;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;EIF4G2;FAM120A;FBL;FMR1;FTO;FUS;FXR2;GTF2F1;HNRNPA1;HNRNPK;HNRNPM;HNRNPU;IGF2BP2;IGF2BP3;ILF3;KHSRP;LARP4B;LIN28;LIN28B;LSM11;MOV10;NOP56;NOP58;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;YWHAG;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME
chr19:39426895-39428210:+
GBMEERIRENSG00000196118.7chr1630759341:30760453:30760605:30760668-0.41512.4780e-048.4239e-08-0.4192imageNFBL;FMR1;NOP56;U2AF2NAT_cells_follicular_helperGSVA_HALLMARK_ADIPOGENESIS
chr19:39426895-39428210:+
GBMEERIRENSG00000125458.2chr1775130224:75130867:75131044:75131105-0.41644.2564e-041.7795e-07-0.4010imageNELAVL1;FBL;FMR1;NOP56;U2AF2NAMonocytesGSVA_HALLMARK_ADIPOGENESIS
chr19:39426895-39428210:+
GBMEERIRENSG00000106077.14chr773736093:73736691:73736928:73736990-0.39896.3083e-041.6298e-07-0.4021imageNFBL;FMR1;NOP56;U2AF2NAMonocytesGSVA_HALLMARK_PEROXISOME
ENSG00000090924.13,PLEKHG2
GBMEAGIRENSG00000099840.9chr192098435:2098450:2098786:2098804-0.33141.6224e-034.6962e-07-0.4459imageNBCCIP;BUD13;CSTF2T;DDX42;EIF4A3;FAM120A;FBL;FMR1;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPK;HNRNPL;HNRNPM;HNRNPU;KHSRP;LIN28;LIN28A;LSM11;NONO;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM10;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;TAF15;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAMonocytesGSVA_HALLMARK_PEROXISOME

More results



Top

5. Enriched editing regions and immune infiltration for PLEKHG2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr19:39426895-39428210:+BLCAEERMacrophages_M11.6923e-030.1930image
ENSG00000090924.13,PLEKHG2BLCAEAGMacrophages_M11.6923e-030.1930image
chr19:39426895-39428210:+BRCAEERMast_cells_resting1.6881e-060.1966image
ENSG00000090924.13,PLEKHG2BRCAEAGMast_cells_resting1.6489e-060.1968image
chr19:39426895-39428210:+CESCEERMacrophages_M19.2708e-030.1787image
ENSG00000090924.13,PLEKHG2CESCEAGMacrophages_M19.2708e-030.1787image
chr19:39426895-39428210:+DLBCEERMast_cells_resting9.3675e-050.5337image
ENSG00000090924.13,PLEKHG2DLBCEAGMast_cells_resting9.3675e-050.5337image
chr19:39426895-39428210:+ESCAEERT_cells_gamma_delta8.3210e-030.2587image
ENSG00000090924.13,PLEKHG2ESCAEAGT_cells_gamma_delta8.2665e-030.2589image
chr19:39426895-39428210:+GBMEERT_cells_CD4_memory_resting1.7770e-030.2460image
ENSG00000090924.13,PLEKHG2GBMEAGT_cells_CD4_memory_resting1.7770e-030.2460image
chr19:39426895-39428210:+HNSCEERNK_cells_resting4.8365e-020.1212image
chr19:39426895-39428210:+KIRPEERB_cells_memory3.2871e-02-0.1966image
ENSG00000090924.13,PLEKHG2KIRPEAGB_cells_memory3.2871e-02-0.1966image
chr19:39426895-39428210:+LGGEERNeutrophils3.4431e-020.1024image
ENSG00000090924.13,PLEKHG2LGGEAGNeutrophils3.4431e-020.1024image
chr19:39426895-39428210:+LIHCEERT_cells_regulatory_(Tregs)7.0042e-03-0.2605image
ENSG00000090924.13,PLEKHG2LIHCEAGT_cells_regulatory_(Tregs)7.0042e-03-0.2605image
chr19:39426895-39428210:+LUADEERNeutrophils2.6945e-02-0.1153image
ENSG00000090924.13,PLEKHG2LUADEAGNeutrophils2.7136e-02-0.1152image
chr19:39426895-39428210:+OVEERT_cells_CD81.9322e-020.1559image
ENSG00000090924.13,PLEKHG2OVEAGT_cells_CD81.4289e-020.1628image
chr19:39426895-39428210:+PAADEERMacrophages_M29.1203e-030.2137image
ENSG00000090924.13,PLEKHG2PAADEAGMacrophages_M29.1203e-030.2137image
chr19:39426895-39428210:+PRADEERT_cells_regulatory_(Tregs)4.0153e-02-0.1678image
ENSG00000090924.13,PLEKHG2PRADEAGT_cells_regulatory_(Tregs)4.0153e-02-0.1678image
chr19:39426895-39428210:+READEERDendritic_cells_activated4.4763e-020.4318image
ENSG00000090924.13,PLEKHG2READEAGDendritic_cells_activated4.4763e-020.4318image
chr19:39426895-39428210:+SKCMEERT_cells_CD84.2079e-030.1737image
ENSG00000090924.13,PLEKHG2SKCMEAGT_cells_CD84.2079e-030.1737image
chr19:39426895-39428210:+TGCTEERMacrophages_M26.4107e-06-0.4036image
ENSG00000090924.13,PLEKHG2TGCTEAGMacrophages_M26.4107e-06-0.4036image
chr19:39426895-39428210:+THCAEERNeutrophils3.5769e-02-0.1035image
ENSG00000090924.13,PLEKHG2THCAEAGNeutrophils3.6439e-02-0.1031image
chr19:39426895-39428210:+THYMEERB_cells_naive1.0627e-070.4972image
ENSG00000090924.13,PLEKHG2THYMEAGB_cells_naive1.0627e-070.4972image
chr19:39426895-39428210:+UCECEEREosinophils1.2008e-020.1994image
ENSG00000090924.13,PLEKHG2UCECEAGEosinophils1.2008e-020.1994image
chr19:39426895-39428210:+UCSEEREosinophils1.9837e-02-0.3133image
ENSG00000090924.13,PLEKHG2UCSEAGEosinophils1.9814e-02-0.3134image


Top

6. Enriched editing regions and immune gene sets for PLEKHG2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr19:39426895-39428210:+BLCAEER4.4102e-02image4.2567e-020.1254image
ENSG00000090924.13,PLEKHG2BLCAEAG4.4102e-02image4.2567e-020.1254image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr19:39426895-39428210:+THYMEER1.2820e-02-0.24574.3822e-02-0.20002.1816e-030.30017.3728e-030.2638image
ENSG00000090924.13,PLEKHG2THYMEAG1.2820e-02-0.24574.3822e-02-0.20002.1816e-030.30017.3728e-030.2638image
chr19:39426895-39428210:+UCECEER1.8720e-030.24564.9873e-040.27389.5182e-030.20571.3248e-020.1967image
ENSG00000090924.13,PLEKHG2UCECEAG1.8767e-030.24554.9981e-040.27389.5392e-030.20561.3269e-020.1966image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000090924.13,PLEKHG2BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6632e-030.1934image
chr19:39426895-39428210:+BLCAGSVA_HALLMARK_MITOTIC_SPINDLEEER1.6632e-030.1934image
ENSG00000090924.13,PLEKHG2BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEAG2.5043e-040.1510image
chr19:39426895-39428210:+BRCAGSVA_HALLMARK_ESTROGEN_RESPONSE_EARLYEER2.5922e-040.1506image
ENSG00000090924.13,PLEKHG2CESCGSVA_HALLMARK_PEROXISOMEEAG1.0926e-030.2233image
chr19:39426895-39428210:+CESCGSVA_HALLMARK_PEROXISOMEEER1.0926e-030.2233image
chr19:39426895-39428210:+COADGSVA_HALLMARK_GLYCOLYSISEER2.5062e-030.3896image
ENSG00000090924.13,PLEKHG2COADGSVA_HALLMARK_GLYCOLYSISEAG2.5062e-030.3896image
chr19:39426895-39428210:+DLBCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.0321e-020.2971image
ENSG00000090924.13,PLEKHG2DLBCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0321e-020.2971image
chr19:39426895-39428210:+ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.5538e-020.2074image
ENSG00000090924.13,PLEKHG2ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.4419e-020.2087image
chr19:39426895-39428210:+GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEER9.1346e-050.3052image
ENSG00000090924.13,PLEKHG2GBMGSVA_HALLMARK_FATTY_ACID_METABOLISMEAG9.1346e-050.3052image
ENSG00000090924.13,PLEKHG2HNSCGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.3131e-030.1960image
chr19:39426895-39428210:+HNSCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.0630e-030.1996image
chr19:39426895-39428210:+KIRCGSVA_HALLMARK_ADIPOGENESISEER3.7972e-070.2832image
ENSG00000090924.13,PLEKHG2KIRCGSVA_HALLMARK_ADIPOGENESISEAG3.7972e-070.2832image
ENSG00000090924.13,PLEKHG2KIRPGSVA_HALLMARK_COAGULATIONEAG4.6897e-040.3170image
chr19:39426895-39428210:+KIRPGSVA_HALLMARK_COAGULATIONEER4.6897e-040.3170image
ENSG00000090924.13,PLEKHG2LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.9673e-090.2782image
chr19:39426895-39428210:+LGGGSVA_HALLMARK_BILE_ACID_METABOLISMEER4.9673e-090.2782image
ENSG00000090924.13,PLEKHG2LIHCGSVA_HALLMARK_MYC_TARGETS_V2EAG7.1852e-06-0.4205image
chr19:39426895-39428210:+LIHCGSVA_HALLMARK_MYC_TARGETS_V2EER7.1852e-06-0.4205image
chr19:39426895-39428210:+LUADGSVA_HALLMARK_APOPTOSISEER8.1905e-030.1376image
ENSG00000090924.13,PLEKHG2LUADGSVA_HALLMARK_APOPTOSISEAG8.1849e-030.1377image
chr19:39426895-39428210:+LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEER5.0997e-050.2485image
ENSG00000090924.13,PLEKHG2LUSCGSVA_HALLMARK_PROTEIN_SECRETIONEAG5.0997e-050.2485image
ENSG00000090924.13,PLEKHG2MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEAG7.7901e-030.3432image
chr19:39426895-39428210:+MESOGSVA_HALLMARK_BILE_ACID_METABOLISMEER7.5082e-030.3447image
chr19:39426895-39428210:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER3.6332e-050.2716image
ENSG00000090924.13,PLEKHG2OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG3.0676e-050.2735image
chr19:39426895-39428210:+PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.2985e-02-0.2038image
ENSG00000090924.13,PLEKHG2PAADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.2985e-02-0.2038image
ENSG00000090924.13,PLEKHG2PCPGGSVA_HALLMARK_MYC_TARGETS_V2EAG2.5693e-02-0.2928image
chr19:39426895-39428210:+PCPGGSVA_HALLMARK_MYC_TARGETS_V2EER2.5693e-02-0.2928image
ENSG00000090924.13,PLEKHG2PRADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.8208e-020.1694image
chr19:39426895-39428210:+PRADGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.8208e-020.1694image
chr19:39426895-39428210:+READGSVA_HALLMARK_BILE_ACID_METABOLISMEER3.3429e-020.4548image
ENSG00000090924.13,PLEKHG2READGSVA_HALLMARK_BILE_ACID_METABOLISMEAG3.3429e-020.4548image
chr19:39426895-39428210:+SARCGSVA_HALLMARK_PROTEIN_SECRETIONEER1.2225e-020.1661image
ENSG00000090924.13,PLEKHG2SARCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.2007e-020.1665image
chr19:39426895-39428210:+SKCMGSVA_HALLMARK_MTORC1_SIGNALINGEER9.4827e-030.1576image
ENSG00000090924.13,PLEKHG2SKCMGSVA_HALLMARK_MTORC1_SIGNALINGEAG9.4827e-030.1576image
chr19:39426895-39428210:+TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER1.7043e-050.3862image
ENSG00000090924.13,PLEKHG2TGCTGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.7043e-050.3862image
ENSG00000090924.13,PLEKHG2THCAGSVA_HALLMARK_PEROXISOMEEAG2.7489e-040.1783image
chr19:39426895-39428210:+THCAGSVA_HALLMARK_PEROXISOMEEER2.7434e-040.1784image
ENSG00000090924.13,PLEKHG2THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG4.7341e-060.4356image
chr19:39426895-39428210:+THYMGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER4.7341e-060.4356image
ENSG00000090924.13,PLEKHG2UCECGSVA_HALLMARK_HEME_METABOLISMEAG8.4112e-060.3461image
chr19:39426895-39428210:+UCECGSVA_HALLMARK_HEME_METABOLISMEER8.3825e-060.3462image
chr19:39426895-39428210:+UCSGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER5.2715e-040.4523image
ENSG00000090924.13,PLEKHG2UCSGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG5.2361e-040.4525image


Top

7. Enriched editing regions and drugs for PLEKHG2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000090924.13,PLEKHG2BLCABIBW2992EAG6.2686e-05-0.2447image
chr19:39426895-39428210:+BLCABIBW2992EER6.2686e-05-0.2447image
chr19:39426895-39428210:+BRCALapatinibEER2.1949e-02-0.0950image
ENSG00000090924.13,PLEKHG2BRCALapatinibEAG2.1656e-02-0.0952image
ENSG00000090924.13,PLEKHG2CESCJNK.9LEAG2.0305e-04-0.2531image
chr19:39426895-39428210:+CESCJNK.9LEER2.0305e-04-0.2531image
chr19:39426895-39428210:+CHOLElesclomolEER2.1899e-030.5218image
ENSG00000090924.13,PLEKHG2CHOLElesclomolEAG2.1899e-030.5218image
chr19:39426895-39428210:+COADDMOGEER6.3988e-030.3540image
ENSG00000090924.13,PLEKHG2COADDMOGEAG6.3988e-030.3540image
chr19:39426895-39428210:+DLBCElesclomolEER6.1019e-030.3903image
ENSG00000090924.13,PLEKHG2DLBCElesclomolEAG6.1019e-030.3903image
chr19:39426895-39428210:+ESCAAZD8055EER3.1266e-020.2124image
ENSG00000090924.13,PLEKHG2ESCAAZD8055EAG3.3546e-020.2097image
chr19:39426895-39428210:+GBMBAY.61.3606EER1.1584e-030.2554image
ENSG00000090924.13,PLEKHG2GBMBAY.61.3606EAG1.1584e-030.2554image
chr19:39426895-39428210:+HNSCBMS.536924EER2.2452e-030.1869image
ENSG00000090924.13,PLEKHG2HNSCBMS.536924EAG2.4522e-030.1853image
chr19:39426895-39428210:+KIRCBI.2536EER9.4282e-040.1866image
ENSG00000090924.13,PLEKHG2KIRCBI.2536EAG9.4282e-040.1866image
chr19:39426895-39428210:+KIRPCHIR.99021EER2.4086e-05-0.3798image
ENSG00000090924.13,PLEKHG2KIRPCHIR.99021EAG2.4086e-05-0.3798image
ENSG00000090924.13,PLEKHG2LGGBMS.708163EAG1.4733e-10-0.3036image
chr19:39426895-39428210:+LGGBMS.708163EER1.4733e-10-0.3036image
chr19:39426895-39428210:+LIHCBMS.509744EER6.8048e-040.3248image
ENSG00000090924.13,PLEKHG2LIHCBMS.509744EAG6.8048e-040.3248image
ENSG00000090924.13,PLEKHG2LUADAICAREAG1.7870e-03-0.1623image
chr19:39426895-39428210:+LUADAICAREER1.8314e-03-0.1619image
chr19:39426895-39428210:+LUSCCCT018159EER8.5067e-03-0.1629image
ENSG00000090924.13,PLEKHG2LUSCCCT018159EAG8.5067e-03-0.1629image
ENSG00000090924.13,PLEKHG2OVABT.263EAG2.4646e-040.2416image
chr19:39426895-39428210:+OVABT.263EER3.6407e-040.2356image
ENSG00000090924.13,PLEKHG2PAADAP.24534EAG2.0707e-030.2512image
chr19:39426895-39428210:+PAADAP.24534EER2.0707e-030.2512image
ENSG00000090924.13,PLEKHG2PCPGKU.55933EAG7.8779e-030.3456image
chr19:39426895-39428210:+PCPGKU.55933EER7.8779e-030.3456image
chr19:39426895-39428210:+PRADKIN001.135EER1.3901e-03-0.2587image
ENSG00000090924.13,PLEKHG2PRADKIN001.135EAG1.3901e-03-0.2587image
ENSG00000090924.13,PLEKHG2READElesclomolEAG3.4478e-020.4525image
chr19:39426895-39428210:+READElesclomolEER3.4478e-020.4525image
chr19:39426895-39428210:+SARCA.443654EER4.5669e-040.2308image
ENSG00000090924.13,PLEKHG2SARCA.443654EAG4.4425e-040.2312image
chr19:39426895-39428210:+SKCMGDC.0449EER1.3961e-020.1495image
ENSG00000090924.13,PLEKHG2SKCMGDC.0449EAG1.3961e-020.1495image
ENSG00000090924.13,PLEKHG2STADEpothilone.BEAG2.8271e-02-0.1456image
chr19:39426895-39428210:+STADEpothilone.BEER2.7988e-02-0.1459image
ENSG00000090924.13,PLEKHG2TGCTLenalidomideEAG7.4127e-07-0.4389image
chr19:39426895-39428210:+TGCTLenalidomideEER7.4127e-07-0.4389image
chr19:39426895-39428210:+THCAAZ628EER3.1619e-040.1766image
ENSG00000090924.13,PLEKHG2THCAAZ628EAG3.2486e-040.1762image
chr19:39426895-39428210:+THYMGW843682XEER1.0358e-080.5297image
ENSG00000090924.13,PLEKHG2THYMGW843682XEAG1.0358e-080.5297image
ENSG00000090924.13,PLEKHG2UCECBryostatin.1EAG1.2407e-050.3400image
chr19:39426895-39428210:+UCECBryostatin.1EER1.2332e-050.3401image
ENSG00000090924.13,PLEKHG2UCSCGP.082996EAG1.0460e-02-0.3426image
chr19:39426895-39428210:+UCSCGP.082996EER1.0452e-02-0.3426image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType